You can help expand this article with text translated from the corresponding article in German. (March 2021) Click [show] for important translation instructions.
|
Clinical data | |
---|---|
Trade names | Avigan (アビガン, Abigan), Avifavir,[1] Areplivir,[2] others |
Other names | T-705, favipira, favilavir |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C5H4FN3O2 |
Molar mass | 157.104 g·mol−1 |
3D model (JSmol) | |
| |
|
Favipiravir, sold under the brand name Avigan among others,[3] is an antiviral medication used to treat influenza in Japan.[4] It is also being studied to treat a number of other viral infections, including SARS-CoV-2.[4] Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.[5]
It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014.[6] In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co.[7] It became a generic drug in 2019.[citation needed]
Avifavir
was invoked but never defined (see the help page).Areplivir
was invoked but never defined (see the help page).Shi2020
was invoked but never defined (see the help page).